Genetic studies have brought a great contribution to the understanding and treatment of many conditions and diseases. Scientists from Australia are hoping to explain the mechanisms behind ovarian cancer and possibly come up with a more effective form of therapy
Ovarian cancer is one of the most common and deadly types of malignancy worldwide. Because of the lack of awareness and the fact that signs are often neglected, conventional treatments are not always efficient enough.
Caroline Ford, a leading researcher at the University of New South Wales in Australia, has been doing important research, focusing on two genes that appear mostly at the initial stages of development. ROR1 and ROR2 are thought to be responsible for promoting metastasis and the rapid growth and spread of tumors.
She addresses the issue by saying: “I hope that through our work we can make it easier for women to be tested for gynecological cancers and that as a society we can remove the awkwardness and stigma that prevents women seeking medical advice.”
Mrs. Ford is eager to replicate and further the results of a clinical test for Cirmtuzumab, a drug that targets ROR1 in patients with chronic lymphocytic leukemia and apply it to ovarian cancer. If successful, she is hoping that it might open the door for other types of cancer, in particular endometrial. Even though it has a lower mortality rate, a significant percentage of patients develop an aggressive form of the disease.
“For those with a less aggressive type of endometrial cancer, the treatment is more often than not a hysterectomy, which still means they must undergo major invasive surgery”, she noted.
With determined and dedicated doctors, such as Caroline Ford, it seems like only a matter of time before more efficient personalized treatments specifically tailored for each patient to become the standard form of therapy.